Repligen has announced that it acquired the assets of BioFlash Partners for $1.8 million, which includes a technology platform for the production of pre-packed, ?plug and play? chromatography columns.
Repligen has announced that it acquired the assets of BioFlash Partners for $1.8 million, which includes a technology platform for the production of pre-packed, ‘plug and play’ chromatography columns.
According to the company this technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins.
“We are very pleased to have acquired the BioFlash platform, a technology which will enable us to meet the growing market need for flexible, pre-packed chromatography products,” said Walter C. Herlihy, president and CEO of Repligen in a statement.
The company reports that products based on the acquired technology will be offered in a range of column diameters and bed heights and can be prepacked with commercially available chromatography resins including immobilized Protein A.
The terms of the acquisition also include a contingent milestone and royalties based on product sales.
